Literature DB >> 31150644

Digoxin Use and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction.

Syed Z Qamer1, Awais Malik1, Essraa Bayoumi2, Phillip H Lam2, Steven Singh1, Milton Packer3, Ioannis E Kanonidis4, Charity J Morgan5, Ahmed Abdelmawgoud6, Richard M Allman7, Gregg C Fonarow8, Ali Ahmed9.   

Abstract

BACKGROUND: Heart failure is a leading cause for hospital readmission. Digoxin use may lower this risk in patients with heart failure with reduced ejection fraction (HFrEF), but data on contemporary patients receiving other evidence-based therapies are lacking.
METHODS: Of the 11,900 patients with HFrEF (ejection fraction ≤45%) in Medicare-linked OPTIMIZE-HF, 8401 were not on digoxin, of whom 1571 received discharge prescriptions for digoxin. We matched 1531 of these patients with 1531 not receiving digoxin by propensity scores for digoxin use. The matched cohort (n = 3062; mean age, 76 years; 44% women; 14% African American) was balanced on 52 baseline characteristics. We assembled a second matched cohort of 2850 patients after excluding those with estimated glomerular filtration rate <15 mL/min/1.73 m2 and heart rate <60 beats/min. Hazard ratios (HRs) and 95% confidence intervals (CIs) for digoxin-associated outcomes were estimated in the matched cohorts.
RESULTS: Among the 3062 matched patients, digoxin use was associated with a significantly lower risk of heart failure readmission at 30 days (HR, 0.74; 95% CI, 0.59-0.93), 1 year (HR, 0.81; 95% CI, 0.72-0.92), and 6 years (HR, 0.90; 95% CI 0.81-0.99). The association with all-cause readmission was significant at 1 and 6 years but not 30 days. There was no association with mortality. Similar associations were observed among the 2850 matched patients without bradycardia or renal insufficiency.
CONCLUSIONS: Among hospitalized older patients with HFrEF receiving contemporary treatments for heart failure, digoxin use is associated with a lower risk of hospital readmission but not all-cause mortality. Published by Elsevier Inc.

Entities:  

Keywords:  Digoxin; Heart failure with reduced ejection fraction; Hospital readmission

Year:  2019        PMID: 31150644     DOI: 10.1016/j.amjmed.2019.05.012

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  3 in total

Review 1.  Effects of Digoxin in Heart Failure (HF) With Reduced Ejection Fraction (EF).

Authors:  Riya R Parikh; Khushbu R Patel; Joseph V Pergolizzi; Frank Breve; Peter Magnusson
Journal:  Cureus       Date:  2022-03-02

Review 2.  Heart Failure with Preserved Ejection Fraction: Pathogenesis, Diagnosis, Exercise, and Medical Therapies.

Authors:  Qingyi Zhan; Wenjing Peng; Siqi Wang; Juan Gao
Journal:  J Cardiovasc Transl Res       Date:  2022-09-28       Impact factor: 3.216

3.  Utilization of Digoxin among Hospitalized Older Patients with Heart Failure and Atrial Fibrillation in Thailand: Prevalence, Associated Factors, and Clinical Outcomes.

Authors:  Noppaket Singkham; Yuttana Wongsalap; Duangkamon Poolpun; Sirichok Phetnoo; Chuthalak Somkhon
Journal:  Ann Geriatr Med Res       Date:  2021-12-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.